SFX-01 is under clinical development by Stalicla and currently in Phase I for Autism Spectrum Disorder (ASD). According to GlobalData, Phase I drugs for Autism Spectrum Disorder (ASD) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SFX-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SFX-01 overview
SFX-01 is under development for the treatment of familial adenomatous polyposis, human epidermal growth factor receptor 2 (her2) negative metastatic breast cancer, chronic kidney disease, glioblastoma, rhabdomyosarcoma, autism spectrum disorder (ASD) Phenotype 2, colorectal cancer and malignant glioma. It is administered orally. The drug candidate is a stabilized synthetic version of sulforaphane. The drug candidate acts by targeting the mutated kelch like ECH associated protein 1 (KEAP1). The drug candidate is developed based on DEPI (Databased Endophenotyping Patient Identification) technology and Sulforadex technology.
It was also under development for the treatment of Parkinson's disease, chronic obstructive pulmonary disease (COPD), acute lymphoblastic leukemia (ALL), juvenile myelomonocytic leukaemia (JMML), multiple sclerosis, osteoarthritis, osteoporosis, cerebral vasospasm, the incidence of delayed cerebral ischemia, prostate cancer, and non-alcoholic fatty liver disease (NAFLD), acute myelocytic leukemia, subarachnoid hemorrhage,community acquired pneumonia and acute respiratory distress syndrome associated with COVID-19 and cardiovascular diseases.
Stalicla overview
Stalicla is a biotechnology company developing precision medicine treatments for patients with Neurodevelopmental disorders. Stalicla is headquartered in Geneva, Switzerland.
For a complete picture of SFX-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
